CN107088226A - 他喷他多的胃肠外给药 - Google Patents

他喷他多的胃肠外给药 Download PDF

Info

Publication number
CN107088226A
CN107088226A CN201710217173.2A CN201710217173A CN107088226A CN 107088226 A CN107088226 A CN 107088226A CN 201710217173 A CN201710217173 A CN 201710217173A CN 107088226 A CN107088226 A CN 107088226A
Authority
CN
China
Prior art keywords
composition
still
tapentadol
administration
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710217173.2A
Other languages
English (en)
Chinese (zh)
Inventor
T.克里斯托弗
S.K.K.英赫尔布雷希特
R.C.A.恩布雷希茨
E.武尔斯滕
K.席内
M.席勒
P.布洛姆斯-芬克
U.莱茵霍尔德
U.法伊尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grünenthal GmbH
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CN107088226A publication Critical patent/CN107088226A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201710217173.2A 2011-03-04 2012-03-02 他喷他多的胃肠外给药 Pending CN107088226A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161449317P 2011-03-04 2011-03-04
US61/449317 2011-03-04
EP11003602.7 2011-05-03
EP11003602 2011-05-03
CN201280011685.9A CN103501775A (zh) 2011-03-04 2012-03-02 他喷他多的胃肠外给药

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280011685.9A Division CN103501775A (zh) 2011-03-04 2012-03-02 他喷他多的胃肠外给药

Publications (1)

Publication Number Publication Date
CN107088226A true CN107088226A (zh) 2017-08-25

Family

ID=44653043

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710217173.2A Pending CN107088226A (zh) 2011-03-04 2012-03-02 他喷他多的胃肠外给药
CN201280011685.9A Pending CN103501775A (zh) 2011-03-04 2012-03-02 他喷他多的胃肠外给药

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280011685.9A Pending CN103501775A (zh) 2011-03-04 2012-03-02 他喷他多的胃肠外给药

Country Status (22)

Country Link
US (3) US20120225951A1 (cg-RX-API-DMAC7.html)
EP (2) EP2680833B1 (cg-RX-API-DMAC7.html)
JP (4) JP2014510067A (cg-RX-API-DMAC7.html)
KR (2) KR101903351B1 (cg-RX-API-DMAC7.html)
CN (2) CN107088226A (cg-RX-API-DMAC7.html)
AU (2) AU2012224953C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013022213A2 (cg-RX-API-DMAC7.html)
CA (1) CA2828635C (cg-RX-API-DMAC7.html)
CY (1) CY1117426T1 (cg-RX-API-DMAC7.html)
DK (1) DK2680833T3 (cg-RX-API-DMAC7.html)
EA (2) EA024193B1 (cg-RX-API-DMAC7.html)
ES (1) ES2573414T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160400T1 (cg-RX-API-DMAC7.html)
HU (1) HUE027514T2 (cg-RX-API-DMAC7.html)
IL (1) IL227825A (cg-RX-API-DMAC7.html)
MX (1) MX348831B (cg-RX-API-DMAC7.html)
PL (1) PL2680833T3 (cg-RX-API-DMAC7.html)
PT (1) PT2680833E (cg-RX-API-DMAC7.html)
RS (1) RS54711B1 (cg-RX-API-DMAC7.html)
SI (1) SI2680833T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012119728A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306479B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011267474B2 (en) 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
EP3685827A1 (en) 2011-03-04 2020-07-29 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
EP3300726A1 (en) * 2011-07-29 2018-04-04 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
BR112015009839A2 (pt) * 2012-11-01 2017-07-11 Torrent Pharmaceuticals Ltd composição farmacêutica de tapentadol para administração parenteral
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
CN103735500B (zh) * 2014-01-28 2016-01-20 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
JP6923447B2 (ja) * 2015-03-27 2021-08-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口投与のための安定な製剤
EP3515412B1 (en) * 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
CN113825500A (zh) * 2019-05-16 2021-12-21 奈克瑟斯药物公司 包含麻黄碱或麻黄碱盐的组合物及其制备和使用方法
EP4011369A1 (en) * 2020-12-14 2022-06-15 G.L. Pharma GmbH Aqueous pharmaceutical composition comprising tapentadol tartrate
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997621A (zh) * 2004-06-28 2007-07-11 格吕伦塔尔有限公司 (-)-(1r,2r)-3-(3-二甲基氨基-1-乙基-2-甲基丙基)-苯酚盐酸盐的晶形
US20080269326A1 (en) * 2007-03-12 2008-10-30 Gruenenthal Gmbh Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain
CN101426485A (zh) * 2006-04-28 2009-05-06 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334422D0 (en) * 1983-12-23 1984-02-01 Sterwin Ag Composition
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
JP2004516233A (ja) * 2000-04-27 2004-06-03 ファイザー・プロダクツ・インク 哺乳動物の細菌若しくは原生動物感染症を治療するか又は予防するためのアザライド抗生組成物の使用
EP1282416A2 (en) * 2000-05-19 2003-02-12 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
JP4905616B2 (ja) * 2001-04-19 2012-03-28 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040180915A1 (en) * 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
AR053304A1 (es) 2004-07-01 2007-05-02 Gruenenthal Gmbh Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.
CA2606947A1 (en) * 2005-04-28 2006-11-02 Theraquest Biosciences Llc Methods and compositions for treating pain
EP1965828A2 (en) * 2005-12-02 2008-09-10 Nastech Pharmaceutical Company Inc. Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
CN101431990B (zh) * 2006-04-28 2011-08-03 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-酚和对乙酰氨基酚的药物结合
SI2046726T1 (sl) * 2006-07-24 2010-05-31 Janssen Pharmaceutica Nv Priprava R R metoksifenil N N trimetilpentanamina
EP1905440A1 (de) * 2006-09-06 2008-04-02 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
JP2008266168A (ja) * 2007-04-18 2008-11-06 Teika Seiyaku Kk 眼科用剤
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
MX2010005680A (es) 2007-11-23 2010-12-21 Protect Pharmaceutical Corp Composiciones de tapentadol.
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
WO2010025931A2 (en) * 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
CN101961315B (zh) * 2010-09-10 2012-09-05 海南美兰史克制药有限公司 一种门冬氨酸鸟氨酸脂质体注射液

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997621A (zh) * 2004-06-28 2007-07-11 格吕伦塔尔有限公司 (-)-(1r,2r)-3-(3-二甲基氨基-1-乙基-2-甲基丙基)-苯酚盐酸盐的晶形
CN101426485A (zh) * 2006-04-28 2009-05-06 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
US20080269326A1 (en) * 2007-03-12 2008-10-30 Gruenenthal Gmbh Use of 1-Phenyl-3-Dimethylamino-propane Compounds for Treating Neuropathic Pain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘肖平: "双重功效镇痛药他喷他多的药理学研究与临床应用", 《实用疼痛学杂志》 *
张强等: "《药剂学》", 31 January 2005 *

Also Published As

Publication number Publication date
JP2023075244A (ja) 2023-05-30
JP2022033863A (ja) 2022-03-02
EA201300990A1 (ru) 2014-02-28
HK1194964A1 (zh) 2014-10-31
IL227825A0 (en) 2013-09-30
PL2680833T3 (pl) 2016-08-31
ZA201306479B (en) 2014-05-28
ES2573414T3 (es) 2016-06-07
EA024193B1 (ru) 2016-08-31
CY1117426T1 (el) 2017-04-26
HUE027514T2 (en) 2016-10-28
CA2828635A1 (en) 2012-09-13
IL227825A (en) 2017-07-31
KR101903351B1 (ko) 2018-10-04
KR20140017587A (ko) 2014-02-11
US20200215003A1 (en) 2020-07-09
KR20180064568A (ko) 2018-06-14
KR101970468B1 (ko) 2019-04-19
DK2680833T3 (en) 2016-05-23
AU2012224953B2 (en) 2017-01-05
EP3025710A1 (en) 2016-06-01
AU2012224953A1 (en) 2013-09-19
SI2680833T1 (sl) 2016-06-30
AU2017202214B2 (en) 2019-02-14
MX348831B (es) 2017-06-30
AU2017202214A1 (en) 2017-04-27
JP2018021050A (ja) 2018-02-08
JP6837944B2 (ja) 2021-03-03
EP2680833B1 (en) 2016-03-02
WO2012119728A1 (en) 2012-09-13
CA2828635C (en) 2020-01-14
US20160106688A1 (en) 2016-04-21
EA028149B1 (ru) 2017-10-31
US20120225951A1 (en) 2012-09-06
CN103501775A (zh) 2014-01-08
RS54711B1 (sr) 2016-08-31
EP2680833A1 (en) 2014-01-08
AU2012224953C1 (en) 2017-07-13
HRP20160400T1 (hr) 2016-05-20
MX2013010046A (es) 2013-12-16
EA201600088A1 (ru) 2016-07-29
PT2680833E (pt) 2016-06-09
BR112013022213A2 (pt) 2017-05-02
JP2014510067A (ja) 2014-04-24

Similar Documents

Publication Publication Date Title
JP6837944B2 (ja) タペンタドールの非経口的投与
EP2680832B1 (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
US8314083B2 (en) Non-sedating antihistamine injection formulations and methods of use thereof
CN111297803A (zh) S-盐酸氯胺酮的药物组合物
KR20150132381A (ko) S-케타민 하이드로클로라이드의 약제학적 조성물
JP2019142972A (ja) タペンタドールの非経口的投与
HK1240495A1 (en) Parenteral administration of tapentadol
HK1224568A1 (en) Parenteral administration of tapentadol
HK1194964B (en) Parenteral administration of tapentadol
US20190388364A1 (en) Tapentadol as a local anesthetic
HK1250655B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
HK1194965B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
HK1194965A (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
HK1250655A1 (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
HK40030923A (en) Aqueous pharmaceutical formulation of tapentadol for oral administration

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1240495

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20170825

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1240495

Country of ref document: HK